AI/ML

 

 

Medicine is data driven. Gone are the days of the chancing alchemist and in with the data. Relationships far too complexed for our minds to decipher are becoming unravelled thanks to AI and heaps of Big Data. Learn how companies are leveraging new opportunities here to extract meaning and correlate increasingly complexed systems biology and drug discovery platforms.
 

THIS YEAR’S WORLD LEADING AI/ML SPEAKERS

 

 

 

AI & ML, Tuesday 2 November 2021

08:40

Opening Remarks

Trevor Howe
09:00

Looking at the bigger picture: How do we make sure that we have the full picture with big data experiments

Joachim Reischl
09:20

Deep Medicine – towards the next generation of software-based precision medicine diagnostics

  • Evolution of precision medicine
  • AI in predicting clinical outcome
  • Software as Medical Device as Companion Diagnostic
Panel discussion
09:40

Essential Tools for Accelerating Pipeline Productivity & Success

What tools are in your toolkit? Join this leading biopharma panel discussion to find out how to give your AI-based drug discovery and development program a competitive edge and increase program success.
10:40

Networking Break

AI & ML
11:35

Chair's Remarks

Edmon Begoli
AI & ML
11:40

Operationalising AI ML – Specific application for AI Transformers. Trustworthy reliant AI

Panel discussion
AI & ML
12:00

Sponsor

AI & ML
12:40

AWS

Adrien Rousset
AI & ML
13:00

A Federated Approach for Academic Collaborations to bring Models to the Next Level

13:20

Networking Lunch Break

AI & ML
15:00

Biorelate

Bjorn Schuller
AI & ML
15:20

Ambient Personalised Health Intelligence: T-minus 3

  • AI for mHealth and IoT for Health
  • Examples from neurodevelopment to neurodegenerative, and psychological disorders to COVID-19
  • 3 Steps towards getting it „out there“
AI & ML
15:40

TEMPUS

Anders Broo
AI & ML
16:00

Recent development in data science and AI will enable workflows that allows historical data to inform design decisions for drug substance and drug product development

  • Knowledge graphs in route design
  • Recommending system in purification & separation science
  • Image analysis in intracellular drug deliver
16:20

Networking Break

AI & ML
17:00

Owkin Connect

AI & ML
17:20

Causaly

Zheng Yang
AI & ML
17:40

How to Motivate and Enable Enterprise Level Data Science Education and Collaboration across Boehringer Ingelheim

18:00

Neri & Sons Band & Networking Drinks Reception

last published: 27/Jul/21 14:25

AI & ML, Wednesday 3 November 2021

Steffen Roellinger
09:00

Decentralised Clinical Trials

  • Discussing the adoption of decentralised clinical trials at Bayer
  • New digital addoption
  • The Bayer trials transformaiton over COVID-19
Andrew Kasarskis
09:00

Digital transformation over COVID-19 – Challenges for the future and perpetuating the efforts

  • COVID-19 lead to digital innovation by necessity, including telehealth, new apps and digital technologies, and data fusion and sharing advances.
  • Large opportunities exist to do much better with learning from data, however.This requires the following operational and cultural change:
-Proactive collection and use of coherent data sets as a baseline for public health and the infrastructure development to support that work.-Recommitment to evidence-based medicine and timely, rigorous assessment of clinical utility through ongoing clinical research with well-powered studies of strong statistical design coupled to careful monitoring of large observational data.
Said Ismail
09:20

Qatar Genome; Big data from an underrepresented region

  • Overview of the Qatar Genome Project (QGP)
  • Contributions to Middle East Genomics
  • QGP role COVID-19 research
  • Strategy for precision medicine implementation
09:20

SevenBridges

Panel discussion
09:40

BC Platforms - Keynote Panel

Paul Agapow
09:40

How to be right: effective use of clinical models and machine learning in the clinic

    There is an increasing demand for a sophisticated model to predict patient outcomes and suggest treatmentsUnfortunately, most proposed clinical models are not fit for purpose, being biased, unvalidated, or irrelevantHere we suggest best practices for the development and deployment of complex ML algorithms, resulting in more successful and effective models
10:20

Networking Break + Speed Networking

AI & ML
11:15

Chair's Remarks

AI & ML
11:40

Genialis

Nicholas Kelley
AI & ML
12:00

Innovation in AI

Nicholas Kelley, Data Science And A.I. Technical Advisor, Novartis
AI & ML
12:20

SambaNova Systems

Abhimanyu Verma
AI & ML
12:40

Unlocking Enterprise Value from AI @ scale

13:00

Networking Lunch Break

AI & ML
14:40

IQVIA

Gloria Macia
AI & ML
15:00

Patient Data and Digital Transformation

AI & ML
15:20

Modulos

Miika Ahdesmaki
AI & ML
15:40

Data integration and AI mining of pooled drug-CRISPR screens identifies novel targets and resistance to cancer treatments

  • AstraZeneca-CRUK Functional Genomics Centre’s vision is to accelerate the development of new treatments for people with cancer
  • The FGC generates pooled drug-CRISPR screen data for uncovering novel targets to battle resistance to cancer therapies
  • This talks focuses on our FAIR data strategy, integration of drug-CRISPR data with other large scale pre/clinical data sets and AI mining approaches to triage the pooled drug-CRISPR hits with a clear impact on oncology new target strategy
16:00

Networking Break

AI & ML
16:40

Averbis

Valeria De Luca
AI & ML
17:00

Using AI at Novartis

18:00

Drinks Reception

last published: 27/Jul/21 14:25

AI & ML, Thursday 4 November 2021

Scott Chandler
09:00

Genetic Drivers of Response to Immunotherapy: Going Beyond the Tumor

09:20

GenomeSys

Thomas Hach
10:40

The Future of Precision Healthcare – Multi-Omics Humanized

  • Personalization of healthcare, not only of drug treatment, is the future
  • Patient influence, patient data and patient-desired outcomes are the most disruptive factors
  • How can we move from sterile biosignatures to a humanized approach?
AI & ML
12:10

Cyclica

Srikanth Ramakrishnan
AI & ML
12:30

ML Ops Delivery for Pharmaceutical R&D -Transforming Processes for Global Medical Safety

Marion Schwaerzler
AI & ML
14:00

Honing into Humans’ Individual Needs: How Natural Language Processing Helps us to Analyze Text Data More Human-Like

  • After years of standardization of human and patient input for analytics, Natural Language Processing (NLP) provides us the opportunity to capture individual and non-standardizable insights from spoken and written text into all kinds of interactions on a large scale.
  • NLP enables us to analyze the input more human-like and on a larger amount of data than ever before with the aim of putting the individuals' needs into the center of attention of Artificial Intelligence.
  • This talk will be about the journey of a successful NLP team at Bayer, how we got there and what it needs to build digital products enhanced by NLP successfully. We will also touch upon selected examples of digital products enhanced by NLP in the pharma world.
AI & ML
14:30

Sponsor

AI & ML
14:50

Presentation

AI & ML
15:10

Sponsor

Wankyu Kim
AI & ML
15:30

KMAP - Genome-scale Understanding of Drug MoA and Discovery

  • Drug-induced Transcriptome provides rich information on Drug MoA
  • KMAP- Globally Unique Reference Database for ~3000 approved Drugs' Transcriptome
  • KMAP is applicable for MoA, Drug Repositioning, Indication Expansion, and more.
last published: 27/Jul/21 14:25

GET INVOLVED AT BIODATA WORLD CONGRESS

 

 

TO SPONSOR


Alistair Wilmot
alistair.wilmot@terrapinn.com
0207 092 1174

 

 

TO SPEAK


Edward Glanville

edward.glanville@terrapinn.com
0207 092 1042

 

 

MARKETING OPPORTUNITIES


Onika Akhtar
onika.akhtar@terrapinn.com
0207 092 1034